References

Treatment of hepatocellular carcinoma in the precision medicine era: From treatment stage migration to therapeutic hierarchy

10.1002/hep.31187 · ExternalCitation · doi-reference

Yttrium-90 radioembolization for the treatment of solitary unresectable HCC: The LEGACY study

10.1002/hep.31819 · ExternalCitation · doi-reference

Neuronal reshaping of the tumor microenvironment in tumorigenesis and metastasis: Bench to clinic

10.1002/med4.70044 · ExternalCitation · doi-reference

Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

10.1016/j.annonc.2025.02.006 · ExternalCitation · doi-reference

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

10.1016/j.jhep.2021.11.018 · ExternalCitation · doi-reference

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab versus sorafenib for unresectable hepatocellular carcinoma

10.1016/j.jhep.2021.11.030 · ExternalCitation · doi-reference

Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis

10.1016/j.jhep.2024.06.042 · ExternalCitation · doi-reference

Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC

10.1016/j.jhep.2025.03.033 · ExternalCitation · doi-reference

Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma

10.1016/j.jhep.2026.01.006 · ExternalCitation · doi-reference

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial

10.1016/s0140-6736(18)30207-1 · ExternalCitation · doi-reference

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): A randomised, open-label, multicentre phase 3 trial

10.1016/s0140-6736(23)01796-8 · ExternalCitation · doi-reference

Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): A multiregional, randomised, double-blind, placebo-controlled phase 3 study

10.1016/s0140-6736(24)02551-0 · ExternalCitation · doi-reference

Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): A multicentre, randomised, double-blind, phase 3 study

10.1016/s0140-6736(24)02575-3 · ExternalCitation · doi-reference

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): An open-label, randomised, phase 3 trial

10.1016/s0140-6736(25)00403-9 · ExternalCitation · doi-reference

Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): A randomised phase 2/3 trial

10.1016/s0140-6736(25)01720-9 · ExternalCitation · doi-reference

Personalised management of patients with hepatocellular carcinoma: A multiparametric therapeutic hierarchy concept

10.1016/s1470-2045(23)00186-9 · ExternalCitation · doi-reference

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): Final analysis of a randomised phase 3 study

10.1016/s1470-2045(25)00543-1 · ExternalCitation · doi-reference

Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): A randomised multicentre phase 2 trial

10.1016/s2468-1253(20)30290-9 · ExternalCitation · doi-reference

Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): A single-arm phase 2 trial

10.1016/s2468-1253(21)00305-8 · ExternalCitation · doi-reference

Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: A single-arm open-label phase 2 trial

10.1016/s2468-1253(21)00385-x · ExternalCitation · doi-reference

Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: A randomised open-label phase 2 trial

10.1016/s2468-1253(21)00427-1 · ExternalCitation · doi-reference

Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: The Notable-HCC phase 1b trial

10.1038/s41467-024-47420-3 · ExternalCitation · doi-reference

Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma

10.1038/s41590-024-01992-w · ExternalCitation · doi-reference

Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity

10.1038/s43018-021-00234-4 · ExternalCitation · doi-reference

Sorafenib in advanced hepatocellular carcinoma

10.1056/nejmoa0708857 · ExternalCitation · doi-reference

Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization

10.1080/02841850801958890 · ExternalCitation · doi-reference

10.1093/oncolo/oyad331

10.1093/oncolo/oyad331 · ExternalCitation · doi-reference

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma

10.1097/hep.0000000000000466 · ExternalCitation · doi-reference

Tumor mutational burden from circulating tumor DNA predicts recurrence of hepatocellular carcinoma after resection: An emerging biomarker for surveillance

10.1097/sla.0000000000006386 · ExternalCitation · doi-reference

Tryptophan suppresses FTH1-driven ferritinophagy, a key correlate of prognosis in hepatocellular carcinoma

10.1111/cpr.70074 · ExternalCitation · doi-reference

Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma

10.1111/his.14317 · ExternalCitation · doi-reference

Biology and significance of alpha-fetoprotein in hepatocellular carcinoma

10.1111/liv.14223 · ExternalCitation · doi-reference

Randomised, multicentre prospective trial of transarterial chemoembolisation plus sorafenib compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial

10.1136/gutjnl-2019-318934 · ExternalCitation · doi-reference

Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: A phase 2, single-arm study

10.1136/jitc-2022-005457 · ExternalCitation · doi-reference

How to define transarterial chemoembolization failure or refractoriness: A European perspective

10.1159/000343867 · ExternalCitation · doi-reference

Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update

10.1159/000368142 · ExternalCitation · doi-reference

Hepatic function during repeated TACE procedures and prognosis after introducing sorafenib in patients with unresectable hepatocellular carcinoma: Multicenter analysis

10.1159/000480256 · ExternalCitation · doi-reference

Assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach—The ALBI grade

10.1200/jco.2014.57.9151 · ExternalCitation · doi-reference

Feasibility of personalized and tumor-informed circulating tumor DNA assay for early recurrence detection in patients with hepatocellular carcinoma

10.1200/po-24-00934 · ExternalCitation · doi-reference

10.1371/journal.pone.0279786

10.1371/journal.pone.0279786 · ExternalCitation · doi-reference

Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: Systematic review and meta-analyses

10.18632/oncotarget.11644 · ExternalCitation · doi-reference

Long-term overall survival after selective internal radiation therapy for locally advanced hepatocellular carcinomas: Updated analysis of DOSISPHERE-01

10.2967/jnumed.123.266211 · ExternalCitation · doi-reference

10.3389/fonc.2020.580241

10.3389/fonc.2020.580241 · ExternalCitation · doi-reference

10.3390/cancers13225864

10.3390/cancers13225864 · ExternalCitation · doi-reference

10.3390/cancers16213610

10.3390/cancers16213610 · ExternalCitation · doi-reference